Effect of gonadotropins and endometrial thickness on pregnancy outcome in patients with unexplained infertility or polycystic ovarian syndrome undergoing intrauterine insemination

Li, Qing; Zhu, Maoling; Deng, Zhuxiu; Wang, Lihua; Huang, Yi; Ruan, Liming; Hu, Shaofei; Wang, Liping

doi:10.1177/0300060520966538

Cited by 8 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, there was no significant difference in mean endometrial thickness between the L-carnitine group and placebo groups; this indicates that treatment with L-carnitine has no significant impact on endometrial thickness in women with PCOS. It has been documented that endometrial thickness can significantly affect pregnancy outcomes in women with PCOS, 10,11 but, the insignificant variation in endometrial thickness between the L-carnitine group and placebo group will raise the possibility of another determinant of successful pregnancy outcome in women with PCOS treated with L-carnitine. Ismail et al 12 in 2014 had stated that L-carnitine treatment significantly improved endometrial thickness in PCOS women; however, it disagrees with Ismail et al in this regard.…”

Section: Discussionmentioning

confidence: 99%

The Effect of L-carnitine on Apoptotic Markers (Annexin V and Clusterin) in Polycystic Ovarian Syndrome Women undergoing ICSI

Alhussien¹,

Mossa²,

Abood³

2022

IJDDT

View full text Add to dashboard Cite

Background: Despite abnormal apoptosis of granulosa cells is believed to have a role in the pathophysiology of polycystic ovarian syndrome (PCOS), the cellular and molecular processes behind this are unknown. Atresia occurs in developing PCOS follicles, likely facilitated by increased androgen levels. Atretic follicles are eliminated in the absence of tissue injury or inflammation, suggesting that programmed cell death may be the mechanism behind this process. Aim of the Study: The current study evaluated the protective effect of L-carnitine (LC) against programmed cell death and, eventually, endometrial receptivity. Patients and Methods: This prospective case-control research was performed at the Al-Nahrain University’s high institute for infertility diagnosis and assisted reproductive technologies and the Al-Farah Specialist Fertility Center. Sixty women diagnosed with the polycystic ovarian syndrome were recruited in this research and began their IVF/ICSI cycle; clusterin and annexin V were measured as apoptotic markers in the early follicular phase of the cycle CD2-in the serum and in the follicular fluid on the day of ova pickup. Endometrial thickness was assessed by ultrasound examination.Results: Both serum annexin V and clusterin were decreased significantly after treatment (p< 0.05). The mean endometrial thickness in all enrolled women was 5.30 ± 0.70 mm. There was no significant difference in mean endometrial thickness between the study and placebo groups, 5.43 ± 0.63 versus 5.37 ± 0.66 mm, respectively (p = 0.441). There was no significant difference in mean serum annexin V (p = 0.101), but follicular fluid annexin V and serum and follicular fluid clusterin were lower in the study group than in the placebo group in a significant manner (p

show abstract

Section: Discussionmentioning

confidence: 99%

The Effect of L-carnitine on Apoptotic Markers (Annexin V and Clusterin) in Polycystic Ovarian Syndrome Women undergoing ICSI

Alhussien¹,

Mossa²,

Abood³

2022

IJDDT

View full text Add to dashboard Cite

show abstract

“…16,[30][31][32] Li et al found that the increase of endometrial thickness can significantly improve the clinical pregnancy rate after IUI. 33 In addition, study has shown that endometrial thickness has no predictive value for IUI outcomes. 34 Wolff EF et al showed that the pregnancy rate after IUI was significantly increased with the increasing endometrial thickness.…”

Section: Discussionmentioning

confidence: 99%

Low Estradiol Level and Endometrial Thickness on the Day of Endometrial Transformation Influence Clinical Pregnancy After Intrauterine Insemination

Tang,

Yi,

Chen

et al. 2024

IJGM

View full text Add to dashboard Cite

The causes of pregnancy failure after intrauterine insemination (IUI) are controversial. The purpose of this study was to investigate the influencing factors on clinical pregnancy after IUI. Methods: This study retrospectively analyzed 1464 cycles of IUI performed at the Meizhou People's Hospital between March 2014 and June 2023. The χ 2 test and logistic regression analysis was applied to assess the associations between the some factors (maternal age, paternal age, cycle type (natural cycle or ovulation induction cycle), hormone level on the day of endometrial transformation (estradiol (E 2 ), luteinizing hormone (LH), and progesterone (P)), endometrial thickness on the day of endometrial transformation, and forward motile sperm concentration after treatment) and pregnancy failure. Results: Among the 1464 IUI cycles in this study, 268 cycles of assisted reproduction resulted in clinical pregnancy, with a clinical pregnancy rate of 18.3%. During the cycles with clinical pregnancy, there were 25 (12.9%) preterm births and 169 (87.1%) full-term births. The E 2 level on the day of endometrial transformation in clinical pregnancy group was higher than that in the pregnancy failure group (658.79±656.02 vs 561.21±558.83 pg/mL)(P=0.025). The clinical pregnancy group had a higher percentage of endometrial thickness between 8 and 13mm on the day of endometrial transformation than the pregnancy failure group (83.2% vs 75.0%) (P=0.002). The results of regressions analysis showed that low E 2 level on the day of endometrial transformation (<238.3 pg/mL vs ≥238.3 pg/mL: OR 1.493, 95% CI: 1.086-2.052, P=0.014), and endometrial thickness <8mm on the day of endometrial transformation (<8mm vs 8-13mm: OR 1.886, 95% CI: 1.284-2.771, P=0.001) may increase risk of pregnancy failure performed IUI. Conclusion: Low estradiol level, and endometrial thickness on the day of endometrial transformation may increase risk of pregnancy failure performed intrauterine insemination.

show abstract

“…Particularly in women with very thin uterine linings on oral medications or for those patients who failed to respond to oral medications with ovulation. [ 4 , 5 ]. In a large study of 50,473 stimulated IUI cycles performed in women less than 40 years of age, a cut-off of two mature follicles was found to limit the risk of twin pregnancy, obtained good conception outcomes, and minimized the risk of higher-order multiple pregnancies [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

How to dose follitropin delta for the first insemination cycle according to the ESHRE and ASRM guidelines; a retrospective cohort study

et al. 2023

View full text Add to dashboard Cite

Background Follitropin Delta (FD) is indicated exclusively for in-vitro fertilization however, being a gonadotropin it could be used for other purposes. A dosing algorithm exists for FD and IVF but is needed for intrauterine insemination (IUI) cycles. The objective of this study is to determine dosing for FD for the first controlled ovarian hyperstimulation (COH) cycle according to current stimulation guidelines. Results A retrospective study of 157 subjects from a single university fertility center from January 2017 to March 2020, was performed. All patients stimulated with FD for IUI were included. The number of failed, normal, or overstimulation cycles was determined based on stimulating not more than 2 mature follicles. We then stratified the group based on the AFC, AMH, and body weight. Of 157 subjects, 49% stimulated correctly, 5.6% failed and 45.4% overstimulated. An analysis of the COH IUI cycles based on stratification and over or lack of stimulation per published guidelines found that women with a bodyweight < 80 kg or AMH ≥ 1.5 ng/ml or AFC ≥ 10 initially stimulate with FD 2.0 to 3.0mcg daily. For women with an AFC of 6–9 stimulate with Follitropin Delta 3.0mcg daily. For women with an AFC < 6 or serum AMH < 1.5 ng/ml stimulate with FD 3.0–4.0mcg daily. For women with body weight > 80 kg stimulate initially with daily with 4.0–6.0mcg FD. Conclusions Follitropin Delta can be used safely for controlled ovarian stimulation and insemination at doses easily dispensed by the current methods of delivery, within the current published guidelines for follicle development.

show abstract

Effect of gonadotropins and endometrial thickness on pregnancy outcome in patients with unexplained infertility or polycystic ovarian syndrome undergoing intrauterine insemination

Cited by 8 publications

References 31 publications

The Effect of L-carnitine on Apoptotic Markers (Annexin V and Clusterin) in Polycystic Ovarian Syndrome Women undergoing ICSI

The Effect of L-carnitine on Apoptotic Markers (Annexin V and Clusterin) in Polycystic Ovarian Syndrome Women undergoing ICSI

Low Estradiol Level and Endometrial Thickness on the Day of Endometrial Transformation Influence Clinical Pregnancy After Intrauterine Insemination

How to dose follitropin delta for the first insemination cycle according to the ESHRE and ASRM guidelines; a retrospective cohort study

Contact Info

Product

Resources

About